Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Bifunctional dihydrofolate reductase-thymidylate synthase (DHFR-TS) is a key enzyme in folate metabolism, catalyzing essential reactions for the synthesis of DNA precursors, glycine, and purines. This bifunctional protein is especially notable in protozoa and some lower eukaryotes, where it exists as a single polypeptide with two distinct enzymatic domains: an N-terminal DHFR domain and a C-terminal TS domain, separated by a linker peptide. It is essential for de novo synthesis of thymidylate—a precursor needed exclusively for DNA replication—and thus critical for cell proliferation. DHFR inhibitors like methotrexate are widely used anticancer agents; however, bifunctional DHFR–TS enzymes found in protozoan pathogens often show resistance or reduced sensitivity to classical antifolates used against human targets. It has been validated genetically/chemically as an antiparasitic drug target.
DHFR inhibition, TS inhibition
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bifunctional dihydrofolate reductase-thymidylate synthase (DHFR-TS).